Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carotid Plaque Regression With Statin Treatment Assessed by High Field Magnetic Resonance Imaging (MRI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00388843
Recruitment Status : Withdrawn (PI has left institution)
First Posted : October 17, 2006
Last Update Posted : August 24, 2015
Sponsor:
Information provided by:
Medical College of Wisconsin

Brief Summary:
The purpose of the study is to determine if short term (6 months) treatment with statins to lower low-density lipoprotein (LDL) in vascular disease patients with carotid plaque will be associated with a measurable reduction in carotid plaque volume using 3 Tesla MRI. The researchers will correlate the change in plaque volume to degree of LDL lowering. The researchers will also study if brief treatment will lead to change in plaque composition. The researchers will compare the change in plaque volume measured by 3T MRI with plaque burden measured by ultrasound.

Condition or disease
Carotid Atherosclerosis

Detailed Description:

Atherosclerotic vascular disease is the leading cause of death in the United States. Atherosclerosis develops with increasing plaque burden and eccentric arterial wall expansion or remodeling, later leading to luminal obstruction. More than 90% of patients with CAD have carotid plaques. Statins have been shown to cause plaque regression in the carotid and coronary arteries. However, there is ongoing controversy about how low the target LDL should be in atherosclerotic patients. The benefits of aggressive LDL lowering with higher statin doses are counterbalanced by the potential for liver and muscle toxicity. High field (3 Tesla) MRI is a promising new modality for measuring plaque volume with high spatial resolution. It is not clear whether increasing statin dose will lead to plaque volume reduction in the short-term (6 months) that can be measured by this new modality.

The primary aim of the study is to determine if LDL lowering using statins in vascular disease patients with carotid plaque will be associated with measurable reduction in carotid plaque volume in the short term (6 months) using 3T MRI.

The four secondary aims of the study are as follows:

To compare the short term carotid plaque volume change using high field MRI in vascular disease patients whose statin dose was increased (dose increased) versus those whose statin dose was maintained (dose maintained).

To determine if increasing statin dose in patients with carotid plaque will lead to measurable change in carotid plaque composition in the short term (6 months) using 3T MRI.

To compare the carotid plaque volume change using 3T MRI with change in plaque burden score using carotid ultrasound .

To determine the relationship between change in plaque volume with change in lipid levels (total cholesterol, LDL, HDL) and change in inflammatory markers (cytokines, high sensitivity CRP).

The study is significant because it will provide insight into optimal statin treatment for atherosclerotic disease. It will also test a new modality for measurement of plaque burden. A reliable and sensitive test with high spatial resolution that accurately measures change in plaque volume will be helpful in assessing response to treatment and as a tool for future clinical trials in assessing efficacy of new treatment modalities that may reduce the need for expensive, long term studies that rely on clinical events for outcome measurement.

Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Short Term Carotid Plaque Regression in Patients With Atherosclerotic Disease Taking Statins Assessed by High Field MRI
Study Start Date : August 2006
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine


Group/Cohort
Dose Increased
Patients presenting with symptoms of coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, and whose statin dose is increased to moderate to high dose by their clinicians.
Dose Maintained
Patients presenting with symptoms due to coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, on no statins or whose statin dose was unchanged by their clinicians.



Primary Outcome Measures :
  1. Change in carotid artery plaque volume assessed by carotid MRI at 6 months [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Change in carotid intima media thickness on ultrasound at 6 months [ Time Frame: 6 months ]
  2. Change in plaque composition by carotid MRI at 6 months [ Time Frame: 6 months ]
  3. Change in inflammatory markers at 6 months [ Time Frame: 6 months ]
  4. Change in regional wall shear stress in the carotid artery [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with coronary artery disease or suspected cerebrovascular accident who have carotid plaque (> 1.1 mm) and whose statin dose has been increased to moderate or high dose (increased statin dose) or maintained (maintained statin dose).
Criteria

Inclusion criteria:

  • Adult (> 21 years old) patients.
  • Diagnosed with coronary artery disease or suspected cerebrovascular accident.
  • For dose increased subjects, patients whose statin dose or LDL lowering therapy is doubled or increased from standard dose to high dose (see table).
  • For dose maintained subjects, patients whose statin dose or LDL lowering therapy is maintained at standard dose (see table).
  • Standard Dose (reported LDL↓ < 40% from literature)

    • Drug Daily Dose/s: (md/day)
    • atorvastatin 10
    • simvastatin 5, 10, 20
    • pravastatin 10, 20, 40, 80
    • fluvastatin 20, 40, 80
    • lovastatin 10, 20, 40
  • High Dose (reported LDL↓ > 40% from literature)

    • Drug Daily Dose/s (mg/day)
    • atorvastatin 40, 80
    • simvastatin 40, 80
    • lovastatin 80
    • rosuvastatin 5, 10, 20, 40
    • Addition of non-statin lipid transfer (tx) (e.g., ezetimibe, fibrate, niacin) to standard statin dose

Exclusion criteria:

  • severe claustrophobia causing inability to undergo MRI implanted ferromagnetic materials (pacemakers, defibrillators, TENS units, aneurysm clips, etc.) that are not suitable for MRI in the clinical setting
  • patients anticipated to undergo carotid stenting or surgery in next 6 months
  • patients unable to lie flat for 1 hour
  • patients requiring supplemental oxygen
  • pregnant women
  • patients who could not be followed up for 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00388843


Locations
Layout table for location information
United States, Wisconsin
Medical College of Wisconsin/Froedtert Memorial and Lutheran Hospital
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Layout table for investigator information
Principal Investigator: Raymond Migrino, MD Medical College of Wisconsin
Additional Information:
Layout table for additonal information
Responsible Party: Raymond Q. Migrino, Department of Medicine, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT00388843    
Other Study ID Numbers: PRO00002285
First Posted: October 17, 2006    Key Record Dates
Last Update Posted: August 24, 2015
Last Verified: August 2015
Keywords provided by Medical College of Wisconsin:
carotid atherosclerosis
magnetic resonance imaging
atherosclerosis
ultrasound
inflammation
statins
vulnerable plaque
stroke
Additional relevant MeSH terms:
Layout table for MeSH terms
Carotid Artery Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases